Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 1

Status

Completed 5Active not recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 22Thoracic 19Gastrointestinal 18Sarcoma 14Genitourinary 12CNS 12Breast 10Tumor-Agnostic 6Other solid neoplasm 6Other hematologic neoplasm 5Dermatologic 5Head & Neck 3Lymphoid 2Plasma cell 1Endocrine 1

Conditions

Neoplasm Metastasis 4Neoplasms 2

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × cediranib × Tumor-Agnostic × Clear all
NCT00750841 2026-05-19

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

AstraZeneca

Phase 1 Active not recruiting
64 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00621725 2014-07-15

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

AstraZeneca

Phase 1 Completed
36 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00306891 2012-11-01

Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentinâ„¢)

AstraZeneca

Phase 2 Completed
60 enrolled 13 charts
Tumor-Agnostic

Neoplasms

NCT00748891 2011-07-01

DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)

AstraZeneca

Phase 1 Completed
35 enrolled
Tumor-Agnostic

Neoplasms

NCT00750425 2011-03-10

Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

AstraZeneca

Phase 1 Completed
46 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00503412 2009-01-19

Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors

AstraZeneca

Phase 1 Completed
6 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡